114 related articles for article (PubMed ID: 29162455)
1. Synthesis and biological evaluation of water-soluble derivatives of chiral gossypol as HIV fusion inhibitors targeting gp41.
Yang J; Li LL; Li JR; Yang JX; Zhang F; Chen G; Yu R; Ouyang WJ; Wu SW
Bioorg Med Chem Lett; 2018 Jan; 28(1):49-52. PubMed ID: 29162455
[TBL] [Abstract][Full Text] [Related]
2. Amino acid derivatives of the (-) enantiomer of gossypol are effective fusion inhibitors of human immunodeficiency virus type 1.
An T; Ouyang W; Pan W; Guo D; Li J; Li L; Chen G; Yang J; Wu S; Tien P
Antiviral Res; 2012 Jun; 94(3):276-87. PubMed ID: 22426469
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological activity of a novel series of 2,5-disubstituted furans/pyrroles as HIV-1 fusion inhibitors targeting gp41.
Jiang S; Tala SR; Lu H; Zou P; Avan I; Ibrahim TS; Abo-Dya NE; Abdelmajeid A; Debnath AK; Katritzky AR
Bioorg Med Chem Lett; 2011 Nov; 21(22):6895-8. PubMed ID: 21978673
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design, synthesis and biological evaluation of new N-carboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41.
Wang Y; Lu H; Zhu Q; Jiang S; Liao Y
Bioorg Med Chem Lett; 2010 Jan; 20(1):189-92. PubMed ID: 19932616
[TBL] [Abstract][Full Text] [Related]
5. Small molecule fusion inhibitors: design, synthesis and biological evaluation of (Z)-3-(5-(3-benzyl-4-oxo-2-thioxothiazolidinylidene)methyl)-N-(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrroles and related derivatives targeting HIV-1 gp41.
He XY; Lu L; Qiu J; Zou P; Yu F; Jiang XK; Li L; Jiang S; Liu S; Xie L
Bioorg Med Chem; 2013 Dec; 21(23):7539-48. PubMed ID: 23673219
[TBL] [Abstract][Full Text] [Related]
6. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.
Jiang S; Lu H; Liu S; Zhao Q; He Y; Debnath AK
Antimicrob Agents Chemother; 2004 Nov; 48(11):4349-59. PubMed ID: 15504864
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and antiviral activities of novel gossypol derivatives.
Yang J; Zhang F; Li J; Chen G; Wu S; Ouyang W; Pan W; Yu R; Yang J; Tien P
Bioorg Med Chem Lett; 2012 Feb; 22(3):1415-20. PubMed ID: 22226654
[TBL] [Abstract][Full Text] [Related]
8. Development of indole compounds as small molecule fusion inhibitors targeting HIV-1 glycoprotein-41.
Zhou G; Wu D; Snyder B; Ptak RG; Kaur H; Gochin M
J Med Chem; 2011 Oct; 54(20):7220-31. PubMed ID: 21928824
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and anti-H5N1 activity of chiral gossypol derivatives and its analogs implicated by a viral entry blocking mechanism.
Yang J; Chen G; Li LL; Pan W; Zhang F; Yang J; Wu S; Tien P
Bioorg Med Chem Lett; 2013 May; 23(9):2619-23. PubMed ID: 23538114
[TBL] [Abstract][Full Text] [Related]
10. Tannin inhibits HIV-1 entry by targeting gp41.
Lü L; Liu SW; Jiang SB; Wu SG
Acta Pharmacol Sin; 2004 Feb; 25(2):213-8. PubMed ID: 14769212
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, Biological Evaluation, and Molecular Docking Studies of Novel 4-[4-Arylpyridin-1(4H)-yl]benzoic Acid Derivatives as Anti-HIV-1 Agents.
Sepehri S; Soleymani S; Zabihollahi R; Aghasadeghi MR; Sadat M; Saghaie L; Fassihi A
Chem Biodivers; 2017 Dec; 14(12):. PubMed ID: 28834275
[TBL] [Abstract][Full Text] [Related]
12. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
Deng Y; Zheng Q; Ketas TJ; Moore JP; Lu M
Biochemistry; 2007 Apr; 46(14):4360-9. PubMed ID: 17371053
[TBL] [Abstract][Full Text] [Related]
13. An amphiphilic conjugate approach toward the design and synthesis of betulinic acid-polyphenol conjugates as inhibitors of the HIV-1 gp41 fusion core formation.
Liu Y; Ke Z; Wu KY; Liu S; Chen WH; Jiang S; Jiang ZH
ChemMedChem; 2011 Sep; 6(9):1654-64. PubMed ID: 21688394
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and evaluation of indole compounds as novel inhibitors targeting Gp41.
Zhou G; Wu D; Hermel E; Balogh E; Gochin M
Bioorg Med Chem Lett; 2010 Mar; 20(5):1500-3. PubMed ID: 20153190
[TBL] [Abstract][Full Text] [Related]
15. Computer-aided design, synthesis, and biological activity evaluation of potent fusion inhibitors targeting HIV-1 gp41.
Tan JJ; Zhang B; Cong XJ; Yang LF; Liu B; Kong R; Kui ZY; Wang CX; Hu LM
Med Chem; 2011 Jul; 7(4):309-16. PubMed ID: 21568877
[TBL] [Abstract][Full Text] [Related]
16. Anti-HIV-1 Activity Prediction of Novel Gp41 Inhibitors Using Structure-Based Virtual Screening and Molecular Dynamics Simulation.
Sepehri S; Saghaie L; Fassihi A
Mol Inform; 2017 Mar; 36(3):. PubMed ID: 27730744
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological activity of novel 5-((arylfuran/1H-pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-4-ones as HIV-1 fusion inhibitors targeting gp41.
Jiang S; Tala SR; Lu H; Abo-Dya NE; Avan I; Gyanda K; Lu L; Katritzky AR; Debnath AK
J Med Chem; 2011 Jan; 54(2):572-9. PubMed ID: 21190369
[TBL] [Abstract][Full Text] [Related]
18. Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket.
Bai Y; Xue H; Wang K; Cai L; Qiu J; Bi S; Lai L; Cheng M; Liu S; Liu K
Amino Acids; 2013 Feb; 44(2):701-13. PubMed ID: 22961335
[TBL] [Abstract][Full Text] [Related]
19. A synthetic C34 trimer of HIV-1 gp41 shows significant increase in inhibition potency.
Nomura W; Hashimoto C; Ohya A; Miyauchi K; Urano E; Tanaka T; Narumi T; Nakahara T; Komano JA; Yamamoto N; Tamamura H
ChemMedChem; 2012 Feb; 7(2):205-8. PubMed ID: 22247043
[No Abstract] [Full Text] [Related]
20. Synthesis, biophysical characterization, and anti-HIV-1 fusion activity of DNA helix-based inhibitors with a p-benzyloxyphenyl substituent at the 5'-nucleobase site.
Tang Y; Han Z; Guo J; Tian Y; Liu K; Xu L
Bioorg Med Chem Lett; 2018 Jun; 28(10):1842-1845. PubMed ID: 29680665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
